(Medley)-A Phase 2/3 Randomized Double-blind Palivizumab-controlled Study to Evaluate the Safety of MEDI8897 a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus in High-risk Children (MEDLEY)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
